Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Zealand Pharma
Biotech
Zealand's dual agonist tied to 11% weight loss in phase 1b
A higher dose of Zealand Pharma's GLP-1/GLP-2 receptor dual agonist reduced mean body weight by 11.6% after 28 weeks in a phase 1b trial.
Gabrielle Masson
Jun 18, 2025 3:00pm
Weight of market pressures pushes Novo CEO out—Chutes & Ladders
May 23, 2025 8:30am
Galapagos CEO eyes exit as spinout names leader—Chutes & Ladders
Apr 25, 2025 8:30am
Roche pays Zealand $1.6B to codevelop amylin obesity asset
Mar 12, 2025 5:23am
Amylyx preps for GLP-1 launch with new CCO—Chutes & Ladders
Jan 10, 2025 8:30am
FDA hits Zealand Pharma's Gattex challenger with CRL
Dec 19, 2024 4:22pm
